Renal Cell Carcinoma

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

By

When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

By

Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

By

The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

By

A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.

Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies

Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies

By

Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Nonsurgical treatment of small tumor renal cancer may be as effective as radical nephrectomy but with fewer complications

Renal stage carcinoma (RCC) has relatively low mortality rates with respect to cancer diagnoses, as the disease tends to be slow growing.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

By

Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.

A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer

A High Level of Circulating Vitamin D Protein Is Associated With a Decreased Risk of Kidney Cancer

By

Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer.

Lower Costs of Pazopanib for Advanced RCC May Influence Drug Choice

Lower Costs of Pazopanib for Advanced RCC May Influence Drug Choice

By

Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.

Certain Renal Cancer Subtypes Linked to Obesity

Certain Renal Cancer Subtypes Linked to Obesity

By

Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

By

The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.

Heading Toward Personalized Management of Advanced Kidney Cancer

Heading Toward Personalized Management of Advanced Kidney Cancer

By

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

By

Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

By

The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

By

Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

By

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Renal Cell Carcinoma:  How Biomarkers Could Affect Drug Development

Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

By

An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs